The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha 1-adrenoceptors
Ennis, C.; Cox, B.
Journal of Pharmacy and Pharmacology 32(6): 434-435
1980
ISSN/ISBN: 0022-3573 PMID: 6106681 Document Number: 158147
Document emailed within 1 workday
Related Documents
Schuurkes, J.A.; Van Nueten, J.M. 1981: Effects of dopamine and its antagonist domperidone cannot be explained by an effect on alpha 1-adrenergic receptors Archives Internationales de Pharmacodynamie et de Therapie 250(2): 324-327Udvardi, G. 1988: Dopamine antagonist domperidone (Motilium) in everyday clinical practice Therapia Hungarica 36(4): 206-209
Hieble, J.P.; Sulpizio, A.C.; Nichols, A.J.; Willette, R.N.; Ruffolo, R.R. 1988: Pharmacologic characterization of SK&F 104078, a novel alpha-2 adrenoceptor antagonist which discriminates between pre- and postjunctional alpha-2 adrenoceptors Journal of Pharmacology and Experimental Therapeutics 247(2): 645-652
Hillegaart, V.; Ahlenius, S.; Fowler, C.J.; Magnusson, O. 1988: Increased duration of dopamine receptor antagonist-induced effects on both behaviour and striatal dopamine turnover by repeated testing in rats Pharmacology and Toxicology 63(2): 114-117
Ferkany, J.W.; Kyle, D.J.; Willets, J.; Rzeszotarski, W.J.; Guzewska, M.E.; Ellenberger, S.R.; Jones, S.M.; Sacaan, A.I.; Snell, L.D.; Borosky, S. 1989: Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist Journal of Pharmacology and Experimental Therapeutics 250(1): 100-109
DiPalma, J.R. 1990: Metoclopramide: a dopamine receptor antagonist American Family Physician 41(3): 919-924
Gabay, C.; Porter, B.; Fantuzzi, G.; Arend, W.P. 1998: Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo Journal of Immunology 159(12): 5905-5913
Patel, S.; Freedman, S.; Chapman, K.L.; Emms, F.; Fletcher, A.E.; Knowles, M.; Marwood, R.; Mcallister, G.; Myers, J.; Curtis, N.; Kulagowski, J.J.; Leeson, P.D.; Ridgill, M.; Graham, M.; Matheson, S.; Rathbone, D.; Watt, A.P.; Bristow, L.J.; Rupniak, N.M.; Baskin, E.; Lynch, J.J.; Ragan, C.I. 1997: Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor Journal of Pharmacology and Experimental Therapeutics 283(2): 636-647
Schoemaker, H.; Claustre, Y.; Fage, D.; Rouquier, L.; Chergui, K.; Curet, O.; Oblin, A.; Gonon, F.; Carter, C.; Benavides, J.; Scatton, B. 1997: Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity Journal of Pharmacology and Experimental Therapeutics 280(1): 83-97
Hayashi, H.; Onozaki, K. 2010: Interleukin-1(IL-1) alpha, beta, IL-1 receptor (IL-1R), IL-1 receptor antagonist (IL-1ra) Nihon Rinsho. Japanese Journal of Clinical Medicine 68(Suppl 7): 62-66
Hayashi, H.; Onozaki, K. 2005: Interleukin-1 (IL-1) alpha, beta, IL-1 receptor, IL-1 receptor antagonist (IL-1ra) Nihon Rinsho. Japanese Journal of Clinical Medicine 63(Suppl 8): 60-64
Gasiewicz, T.A.; Rucci, G. 1991: Alpha-naphthoflavone acts as an antagonist of 2,3,7, 8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor Molecular Pharmacology 40(5): 607-612
Shibata, S.; Matsunaga, M.; Oikawa, M.; Nitahara, K.; Higa, K. 2005: Severe hypotension after induction of general anesthesia in a patient receiving an angiotensin II receptor antagonist and an alpha-blocker Masui. Japanese Journal of Anesthesiology 54(6): 670-672
Fleishmann, R.M. 2002: Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents Clinical and Experimental Rheumatology 20(5 Suppl 27: S35-S41
Chan, A.M.; Rubin, J.S.; Bottaro, D.P.; Hirschfield, D.W.; Chedid, M.; Aaronson, S.A. 1991: Identification of a competitive HGF antagonist encoded by an alternative transcript Science 254(5036): 1382-1385
Papp, M.; Moryl, E. 1993: New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors Polish Journal of Pharmacology 45(5-6): 549-553
Ninan, I.; Kulkarni, S.K. 1998: Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801 Indian Journal of Physiology and Pharmacology 42(3): 375-382
Rakovska, A.; Henklein, P.; Milenov, K.; Nieber, K.; Oehme, P. 1987: Suc-Tyr(SE)-Met-Gly-Trp-Met-Asp-beta-phenethylamide(410): a competitive antagonist of cholecystokinin-induced contractions in smooth muscles in vitro Methods and Findings in Experimental and Clinical Pharmacology 9(7): 429-435
Rodríguez de Fonseca, F.; Rubio, P.; Menzaghi, F.; Merlo-Pich, E.; Rivier, J.; Koob, G.F.; Navarro, M. 1996: Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats Journal of Pharmacology and Experimental Therapeutics 276(1): 56-64
Neubig, R.R.; Gantzos, R.D.; Brasier, R.S. 1985: Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry Molecular Pharmacology 28(5): 475-486